Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.

J Res Med Sci · 2014 · PMC4274576 · PMID 25538783

Europe PMC

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

almost significantlyP = 0.054so close (0.05 < p ≤ 0.1)

Treatment response was almost significantly different in the topiramate group comparing placebo group ( P = 0.054).

also in 555 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.